keyword
MENU ▼
Read by QxMD icon Read
search

HF10 therapy

keyword
https://www.readbyqxmd.com/read/29105244/spinal-cord-stimulation-for-treating-chronic-pain-reviewing-preclinical-and-clinical-data-on-paresthesia-free-high-frequency-therapy
#1
REVIEW
Krishnan Chakravarthy, Hira Richter, Paul J Christo, Kayode Williams, Yun Guan
BACKGROUND: Traditional spinal cord stimulation (SCS) requires that paresthesia overlaps chronic painful areas. However, the new paradigm high-frequency SCS (HF-SCS) does not rely on paresthesia. STUDY DESIGN: A review of preclinical and clinical studies regarding the use of paresthesia-free HF-SCS for various chronic pain states. METHODS: We reviewed available literatures on HF-SCS, including Nevro's paresthesia-free ultra high-frequency 10 kHz therapy (HF10-SCS)...
November 3, 2017: Neuromodulation: Journal of the International Neuromodulation Society
https://www.readbyqxmd.com/read/29076398/quantitative-imaging-of-po2-in-orthotopic-murine-gliomas-hypoxia-correlates-with-resistance-to-radiation
#2
Hironobu Yasui, Tatsuya Kawai, Shingo Matsumoto, Keita Saito, Nallathamby Devasahayam, James B Mitchell, Kevin Camphausen, Osamu Inanami, Murali C Krishna
Hypoxia is considered one of the microenvironmental factors associated with the malignant nature of glioblastoma. Thus, evaluating intratumoural distribution of hypoxia would be useful for therapeutic planning as well as assessment of its effectiveness during the therapy. Electron paramagnetic resonance imaging (EPRI) is an imaging technique which can generate quantitative maps of oxygen in vivo using the exogenous paramagnetic compound, triarylmethyl and monitoring its line broadening caused by oxygen. In this study, the feasibility of EPRI for assessment of oxygen distribution in the glioblastoma using orthotopic U87 and U251 xenograft model is examined...
October 2017: Free Radical Research
https://www.readbyqxmd.com/read/28861325/the-efficacy-of-combination-therapy-with-oncolytic-herpes-simplex-virus-hf10-and-dacarbazine-in-a-mouse-melanoma-model
#3
Rui Tanaka, Fumi Goshima, Shinichi Esaki, Yoshitaka Sato, Takayuki Murata, Yukihiro Nishiyama, Daisuke Watanabe, Hiroshi Kimura
Advanced melanoma has long been treated with chemotherapy using cytotoxic agents like dacarbazine (DTIC), but overall survival rates with these drugs have been generally low. Recently, immunoregulatory monoclonal antibodies and molecularly targeted therapy with a BRAF inhibitor and/or a MEK inhibitor, have been used to treat malignant melanoma and have improved the survival rate of patients with advanced melanoma. However, high prices of these drugs are problematic. In this study, we evaluated the oncolytic efficacy of HF10, an attenuated, replication-competent HSV, with DTIC in immunocompetent mice model of malignant melanoma...
2017: American Journal of Cancer Research
https://www.readbyqxmd.com/read/28770166/genomic-signature-of-the-natural-oncolytic-herpes-simplex-virus-hf10-and-its-therapeutic-role-in-preclinical-and-clinical-trials
#4
REVIEW
Ibrahim Ragab Eissa, Yoshinori Naoe, Itzel Bustos-Villalobos, Toru Ichinose, Maki Tanaka, Wu Zhiwen, Nobuaki Mukoyama, Taishi Morimoto, Noriyuki Miyajima, Hasegawa Hitoki, Seiji Sumigama, Branko Aleksic, Yasuhiro Kodera, Hideki Kasuya
Oncolytic viruses (OVs) are opening new possibilities in cancer therapy with their unique mechanism of selective replication within tumor cells and triggering of antitumor immune responses. HF10 is an oncolytic herpes simplex virus-1 with a unique genomic structure that has non-engineered deletions and insertions accompanied by frame-shift mutations, in contrast to the majority of engineered OVs. At the genetic level, HF10 naturally lacks the expression of UL43, UL49.5, UL55, UL56, and latency-associated transcripts, and overexpresses UL53 and UL54...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28535555/paresthesia-independence-an-assessment-of-technical-factors-related-to-10-khz-paresthesia-free-spinal-cord-stimulation
#5
MULTICENTER STUDY
Giuliano De Carolis, Mery Paroli, Lara Tollapi, Matthew W Doust, Abram H Burgher, Cong Yu, Thomas Yang, Donna M Morgan, Kasra Amirdelfan, Leonardo Kapural, B Todd Sitzman, Richard Bundschu, Ricardo Vallejo, Ramsin M Benyamin, Thomas L Yearwood, Bradford E Gliner, Ashley A Powell, Kerry Bradley
BACKGROUND: Spinal cord stimulation (SCS) has been successfully used to treat chronic intractable pain for over 40 years. Successful clinical application of SCS is presumed to be generally dependent on maximizing paresthesia-pain overlap; critical to achieving this is positioning of the stimulation field at the physiologic midline. Recently, the necessity of paresthesia for achieving effective relief in SCS has been challenged by the introduction of 10 kHz paresthesia-free stimulation...
May 2017: Pain Physician
https://www.readbyqxmd.com/read/28204731/hf10-therapy-for-chronic-back-pain-in-patients-with-nonoperated-kyphoscoliosis-the-importance-of-preoperative-assessment
#6
Maarten Moens, Ann De Smedt, Lisa Goudman, Peter Mariën, Jo Nijs, Patrick Herregodts, Raf Brouns
No abstract text is available yet for this article.
February 1, 2017: Pain Medicine: the Official Journal of the American Academy of Pain Medicine
https://www.readbyqxmd.com/read/28072810/high-frequency-spinal-cord-stimulation-for-complex-regional-pain-syndrome-a-case-report
#7
Joseph T Crapanzano, Lisa M Harrison-Bernard, Mark R Jones, Alan D Kaye, Erich O Richter, Mordeci N Potash
Complex regional pain syndrome (CRPS) is a chronic, debilitating, neuropathic pain condition which is often misdiagnosed, difficult to manage, and lacks proven methods for remission. Most available methods provide some relief to a small percentage of patients. Recent FDA approval and superiority of the Nevro Senza 10-kHz high frequency (HF10) spinal cord stimulation (SCS) therapy over traditional low-frequency spinal cord stimulation for treatment of chronic back and leg pain may provide a new interventional therapeutic option for patients suffering from CRPS...
January 2017: Pain Physician
https://www.readbyqxmd.com/read/28025843/10-khz-high-frequency-spinal-cord-stimulation-for-chronic-axial-low-back-pain-in-patients-with-no-history-of-spinal-surgery-a-preliminary-prospective-open-label-and-proof-of-concept-study
#8
Adnan Al-Kaisy, Stefano Palmisani, Thomas E Smith, David Pang, Khai Lam, William Burgoyne, Russell Houghton, Emma Hudson, Jonathan Lucas
OBJECTIVE: To explore the effectiveness of 10 kHz high frequency spinal cord stimulation (HF10 therapy) treatment of chronic low back pain in patients who have not had spinal surgery. METHODS: Patients with chronic low back pain without prior spinal surgery were evaluated by a team of spine surgeons to rule out any spinal pathology amenable to surgical interventions and by a multidisciplinary pain team to confirm eligibility for the study. After a successful (>50% back pain reduction) trial of HF10 therapy, enrolled subjects underwent permanent system implantation and were followed-up one year post-implant...
January 2017: Neuromodulation: Journal of the International Neuromodulation Society
https://www.readbyqxmd.com/read/27584814/comparison-of-10-khz-high-frequency-and-traditional-low-frequency-spinal-cord-stimulation-for-the-treatment-of-chronic-back-and-leg-pain-24-month-results-from-a-multicenter-randomized-controlled-pivotal-trial
#9
RANDOMIZED CONTROLLED TRIAL
Leonardo Kapural, Cong Yu, Matthew W Doust, Bradford E Gliner, Ricardo Vallejo, B Todd Sitzman, Kasra Amirdelfan, Donna M Morgan, Thomas L Yearwood, Richard Bundschu, Thomas Yang, Ramsin Benyamin, Abram H Burgher
BACKGROUND: Pain relief with spinal cord stimulation (SCS) has focused historically on paresthesias overlapping chronically painful areas. A higher level evidence supports the use of SCS in treating leg pain than supports back pain, as it is difficult to achieve adequate paresthesia coverage, and then pain relief, in the low back region. In comparison, 10-kHz high-frequency (HF10 therapy) SCS therapy does not rely on intraoperative paresthesia mapping and remains paresthesia-free during therapy...
November 2016: Neurosurgery
https://www.readbyqxmd.com/read/27228514/high-frequency-spinal-cord-stimulation-at-10-khz-for-the-treatment-of-chronic-pain-6-month-australian-clinical-experience
#10
MULTICENTER STUDY
Marc Russo, Paul Verrills, Bruce Mitchell, John Salmon, Adele Barnard, Danielle Santarelli
BACKGROUND: High frequency spinal cord stimulation at 10 kHz (HF10 therapy) represents a prominent advance in spinal cord stimulation (SCS) therapy, having demonstrated enhanced efficacy in patients with back and leg pain and pain relief without paresthesia that is sustained at 24 months post implant. OBJECTIVE: To report on the effectiveness HF10 SCS therapy for a wide range of intractable pain conditions in clinical practice. STUDY DESIGN: Retrospective investigation of 256 patients who trialed HF10 SCS for chronic intractable pain of various etiologies...
2016: Pain Physician
https://www.readbyqxmd.com/read/26218762/novel-10-khz-high-frequency-therapy-hf10-therapy-is-superior-to-traditional-low-frequency-spinal-cord-stimulation-for-the-treatment-of-chronic-back-and-leg-pain-the-senza-rct-randomized-controlled-trial
#11
RANDOMIZED CONTROLLED TRIAL
Leonardo Kapural, Cong Yu, Matthew W Doust, Bradford E Gliner, Ricardo Vallejo, B Todd Sitzman, Kasra Amirdelfan, Donna M Morgan, Lora L Brown, Thomas L Yearwood, Richard Bundschu, Allen W Burton, Thomas Yang, Ramsin Benyamin, Abram H Burgher
BACKGROUND: Current treatments for chronic pain have limited effectiveness and commonly known side effects. Given the prevalence and burden of intractable pain, additional therapeutic approaches are desired. Spinal cord stimulation (SCS) delivered at 10 kHz (as in HF10 therapy) may provide pain relief without the paresthesias typical of traditional low-frequency SCS. The objective of this randomized, parallel-arm, noninferiority study was to compare long-term safety and efficacy of SCS therapies in patients with back and leg pain...
October 2015: Anesthesiology
https://www.readbyqxmd.com/read/26182034/188%C3%A2-randomized-controlled-clinical-trial-evaluating-the-safety-and-effectiveness-of-10-khz-high-frequency-and-traditional-low-frequency-stimulation-for-the-treatment-of-chronic-back-and-leg-pain-18-month-results
#12
Leonardo Kapural, Cong Yu, Matthew W Doust, Bradford E Gliner, Ricardo Vallejo, B Todd Sitzman, Kasra Amirdelfan, Donna M Morgan, Lora L Brown, Thomas L Yearwood, Richard Bundschu, Allen Burton, Thomas Yang, Ramsin Benyamin, Abram H Burgher
INTRODUCTION: A randomized controlled trial with appropriate statistical power and long-term outcomes is the hallmark of level 1 clinical evidence. The SENZA-RCT multicenter pivotal study was powered to directly compare highfrequency spinal cord stimulation (SCS) at 10 kHz (HF10 therapy) and traditional lowfrequency (∼50 Hz) SCS. The comparative efficacy of these modalities for the treatment of chronic back and leg pain for 18 months is presented. METHODS: Baseline assessments were performed before the randomization of 198 patients...
August 2015: Neurosurgery
https://www.readbyqxmd.com/read/26176043/phase-i-dose-escalation-clinical-trial-of-hf10-oncolytic-herpes-virus-in-17-japanese-patients-with-advanced-cancer
#13
Hideki Kasuya, Yasuhiro Kodera, Akimasa Nakao, Kazuo Yamamura, Tan Gewen, Wu Zhiwen, Yoshihiro Hotta, Suguru Yamada, Tsutomu Fujii, Saori Fukuda, Naoko Tsurumaru, Toshie Kuwahara, Toyone Kikumori, Yusuke Koide, Yasushi Fujimoto, Tsutomu Nakashima, Yoshiki Hirooka, Hiroshi Shiku, Maki Tanaka, Kazuto Takesako, Touru Kondo, Branko Aleksic, Hiroki Kawashima, Hidemi Goto, Yukihiro Nishiyama
Oncolytic virus therapy is a promising new therapeutic method, one of an eagerly anticipated class of biological therapies against cancer. There are many different classes of oncolytic virus. One of these, herpes oncolytic virus, is strongly oncolytic and has a large DNA genome as 150k bp. HF10 is a spontaneous mutant of herpes simplex virus -1 (HSV-1) that replicates within tumors and destroys cancers without damaging normal tissue and organs. Clinical trials of HF10 are underway in Japan and the United States...
May 2014: Hepato-gastroenterology
https://www.readbyqxmd.com/read/25377278/10-khz-high-frequency-scs-therapy-a-clinical-summary
#14
REVIEW
Marc Russo, Jean-Pierre Van Buyten
OBJECTIVE: Chronic pain remains a serious public health problem worldwide. A spinal cord stimulation (SCS) therapy called HF10 SCS uses 10-kHz high-frequency stimulation to provide pain relief without paresthesia. In this article, we describe the therapy, device, and the methods of implant and then review the safety and effectiveness data for this therapy. RESULTS: HF10 SCS uses a charge-balanced stimulation waveform that has been shown to be safe in both animal and human studies...
May 2015: Pain Medicine: the Official Journal of the American Academy of Pain Medicine
https://www.readbyqxmd.com/read/25272216/cost-effectiveness-of-a-novel-10-khz-high-frequency-spinal-cord-stimulation-system-in-patients-with-failed-back-surgery-syndrome-fbss
#15
COMPARATIVE STUDY
Lieven Annemans, Jean-Pierre Van Buyten, Thomas Smith, Adnan Al-Kaisy
OBJECTIVES: Spinal cord stimulation (SCS) is an effective method of relieving chronic intractable pain, and one of its key indications is failed back surgery syndrome (FBSS). The objective of the current study was to evaluate the cost effectiveness of 10 kHz high-frequency SCS (HF10 SCS) compared to conventional medical management (CMM), reoperation, and traditional nonrechargeable (TNR-SCS) and rechargeable SCS (TR-SCS). METHODS: A health economic model of SCS in the United Kingdom was reproduced in the perspective of the health care system to simulate costs and quality adjusted life years (QALYs) over 15 years...
2014: Journal of Long-term Effects of Medical Implants
https://www.readbyqxmd.com/read/25156870/combination-therapy-of-oncolytic-herpes-simplex-virus-hf10-and-bevacizumab-against-experimental-model-of-human-breast-carcinoma-xenograft
#16
Gewen Tan, Hideki Kasuya, Tevfik Tolga Sahin, Kazuo Yamamura, Zhiwen Wu, Yusuke Koide, Yoshihiro Hotta, Toshio Shikano, Suguru Yamada, Akiyuki Kanzaki, Tsutomu Fujii, Hiroyuki Sugimoto, Shuji Nomoto, Yoko Nishikawa, Maki Tanaka, Naoko Tsurumaru, Toshie Kuwahara, Saori Fukuda, Toru Ichinose, Toyone Kikumori, Shin Takeda, Akimasa Nakao, Yasuhiro Kodera
Breast cancer is one of the most common and feared cancers faced by women. The prognosis of patients with advanced or recurrent breast cancer remains poor despite refinements in multimodality therapies involving chemotherapeutic and hormonal agents. Multimodal therapy with more specific and effective strategy is urgently needed. The oncolytic herpes simplex virus (HSV) has potential to become a new effective treatment option because of its broad host range and tumor selective viral distribution. Bevacizumab is a monoclonal antibody against VEGFA, which inhibits angiogenesis and therefore tumor growth...
April 1, 2015: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/24308759/sustained-effectiveness-of-10-khz-high-frequency-spinal-cord-stimulation-for-patients-with-chronic-low-back-pain-24-month-results-of-a-prospective-multicenter-study
#17
MULTICENTER STUDY
Adnan Al-Kaisy, Jean-Pierre Van Buyten, Iris Smet, Stefano Palmisani, David Pang, Thomas Smith
OBJECTIVE: The aim of this study was to investigate the long-term efficacy and safety of paresthesia-free high-frequency spinal cord stimulation (HF10 SCS) for the treatment of chronic, intractable pain of the low back and legs. DESIGN: Prospective, multicenter, observational study. METHOD: Patients with significant chronic low back pain underwent implantation of a spinal cord stimulator capable of HF10 SCS. Patients' pain ratings, disability, sleep disturbances, opioid use, satisfaction, and adverse events were assessed for 24 months...
March 2014: Pain Medicine: the Official Journal of the American Academy of Pain Medicine
https://www.readbyqxmd.com/read/24265099/oncolytic-viral-therapy-with-a-combination-of-hf10-a-herpes-simplex-virus-type-1-variant-and-granulocyte-macrophage-colony-stimulating-factor-for-murine-ovarian-cancer
#18
Fumi Goshima, Shinichi Esaki, Chenhong Luo, Maki Kamakura, Hiroshi Kimura, Yukihiro Nishiyama
Ovarian cancer is the most frequent cause of gynecological cancer-related mortality as a majority of patients are diagnosed at an advanced stage with intraperitoneal dissemination because of the absence of initial symptoms. Granulocyte-macrophage colony-stimulating factor (GM-CSF) plays an important role in the maturation of specialized antigen-presenting cells. In this study, we utilized a herpes simplex virus (HSV) amplicon expressing murine GM-CSF combined with HF10 (mGM-CSF amplicon), a highly attenuated HSV type 1 strain functioning as a helper virus to strengthen anti-tumor immune response, for the treatment of ovarian cancer with intraperitoneal dissemination...
June 15, 2014: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/24170435/combination-treatment-of-human-pancreatic-cancer-xenograft-models-with-the-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor-erlotinib-and-oncolytic-herpes-simplex-virus-hf10
#19
Kazuo Yamamura, Hideki Kasuya, Tevfik Tolga Sahin, Gewen Tan, Yoshihiro Hotta, Naoko Tsurumaru, Saori Fukuda, Mitsuro Kanda, Daisuke Kobayashi, Chie Tanaka, Suguru Yamada, Goro Nakayama, Tsutomu Fujii, Hiroyuki Sugimoto, Masahiko Koike, Shuji Nomoto, Michitaka Fujiwara, Maki Tanaka, Yasuhiro Kodera
BACKGROUND: There is the potential to use replication-competent oncolytic viruses to treat cancer. We evaluated the efficacy of HF10, a herpes simplex virus type 1 (HSV-1) mutant, in combination with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in human pancreatic cancer xenograft models. METHODS: The viability of human pancreatic cancer cell lines (BxPC-3 and PANC-1) treated with HF10 and erlotinib, on their own or in combination, was determined...
February 2014: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/23887644/enhancement-of-systemic-tumor-immunity-for-squamous-cell-carcinoma-cells-by-an-oncolytic-herpes-simplex-virus
#20
N Meshii, G Takahashi, S Okunaga, M Hamada, S Iwai, A Takasu, Y Ogawa, Y Yura
RH2 is a neurovirulent γ134.5 gene-deficient herpes simplex virus type 1 (HSV-1) with a lytic ability in human squamous cell carcinoma (SCC) cells; it is related to spontaneously occurring HSV-1 mutant HF10. The effect of RH2 on SCC was examined using a syngeneic C3H mouse model. After infection of mouse SCCVII cells with RH2, cell viability was decreased at first, but recovered by prolonged culture, indicating the limited replication of RH2. The antitumor ability of RH2 was examined using a bilateral SCCVII tumor model...
September 2013: Cancer Gene Therapy
keyword
keyword
77108
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"